Free Trial

Is Eli Lilly a Buy? Analyst Confidence Grows for 2025

New York, United States of America - 2023 March 10: Lilly company on stock market. Lilly financial success and profit — Stock Editorial Photography

Key Points

  • Eli Lilly's price pullback presents investors with an opportunity. The stock has a healthy 25% upside from critical support targets. 
  • Despite tepid results, analysts' consensus is firming around the $1000 level; the outlook and pipeline are robust. 
  • Ebglyss approval in Q3 will sustain the company's growth trajectory in 2025. 
  • 5 stocks we like better than Eli Lilly and Company.

Eli Lilly’s NYSE: LLY market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a rally because of underperformance, but the salient details are that growth is robust, driving impressive profits, and is expected to accelerate in 2025. The net result from the release is that analysts are raising their estimates for Q4, next year, and the next five year’s earnings, creating a tailwind for the LLY market.  

Eli Lilly and Company Today

Eli Lilly and Company stock logo
LLYLLY 90-day performance
Eli Lilly and Company
$753.41 +23.68 (+3.25%)
(As of 11/20/2024 ET)
52-Week Range
$561.65
$972.53
Dividend Yield
0.69%
P/E Ratio
81.45
Price Target
$1,007.94

Competition in Eli Lilly's core market is intense and likely to be a headwind over the coming years, but operational quality must be considered. Eli Lilly is following AbbVie's NYSE: ABBV lead and investing in diversification, which is fueling a robust outlook for sustainable long-term growth. Among the highlights from Q3 is completing an acquisition that bolstered the neurosciences portfolio and the pipeline of potential candidates. 

Regarding the pipeline, the company received two new approvals during the quarter and announced positive results from four last-stage trials that could receive approval within the next 12 to 18 months. One of the approvals is for Ebglyss, a treatment for atopic dermatitis that could displace the current market leader, Dupixent. Dupixent sales in Q3 topped $3.8 billion, or roughly 27% of Eli Lilly’s projected Q4 revenue. 

Eli Lilly Falls After Missing High Bar: Issues Weak Full-Year Guidance

The only problem with Eli Lilly’s Q3 report is that it failed to match the high bar set by analysts. The company’s revenue missed the consensus by 560 basis points but is up 20.5% compared to last year despite divestiture on the strength of Mounjaro and Zepbound, portfolio diversification, and higher prices. 

Eli Lilly and Company MarketRank™ Stock Analysis

Overall MarketRank™
100th Percentile
Analyst Rating
Moderate Buy
Upside/Downside
33.8% Upside
Short Interest Level
Healthy
Dividend Strength
Weak
Environmental Score
-2.25
News Sentiment
1.02mentions of Eli Lilly and Company in the last 14 days
Insider Trading
Selling Shares
Proj. Earnings Growth
79.49%
See Full Analysis

Eli Lilly’s growth is stronger on an adjusted basis, about 42% YoY, and is expected to accelerate in Q4. The non-incretin portfolio, a critical element of the company’s long-term outlook, grew by 17% and will accelerate in Q4 due to the latest acquisition. Morphic Holding is focused on inflammatory bowel disease, a market worth roughly $22 billion, and is expected to grow at a mid-single-digit CAGR over the next eight years. 

The margin news is also mixed but favorable to investors. Although earnings fell short of the consensus, the net income is positive versus a loss in the previous year, and adjusted EPS is up by 1000%. Regarding the guidance, the company trimmed its outlook for revenue and earnings due to acquired IPR&D expenses. However, the new guidance was better than expected, forecasting $14.20 billion in revenue for Q4, up more than 50% as Mounjaro and Zepbound sales accelerate and the divestiture impact disappears. 

Analysts Conviction Firms: Eli Lilly Will Set a New High

The first analyst revisions tracked by MarketBeat include reduced price targets, but the takeaway from the data is positive for shareholders. The reductions are weighing on the market now but show an increasing conviction in the $1009 consensus target, a 25% increase from critical support levels. The two revisions tracked within the first 72 hours of the release put the stock at $975 and $1100, providing a mid-point above the consensus, suggesting even higher highs are possible. 

The technical action in LLY shares following the report is mixed. The market fell hard on the news but bounced from the critical support target and remains above it now. The volume indicates support strength, which spiked to a six-year high. The market may retest support at the $800 level but should stimulate another buying frenzy if it does. 

The biggest risk is competition in the growing GLP-1 marketplace. The latest news is that Viking Therapeutics' VK2735 compound, similar to Lilly’s Zepbound, showed positive results in an early trial with increased weight loss as the dosage increased. Among the advantages is its oral delivery, contrary to injectable Zepbound. 

Eli Lilly LLY stock chart

Should you invest $1,000 in Eli Lilly and Company right now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Thomas Hughes
About The Author

Thomas Hughes

Contributing Author

Technical and Fundamental Analysis

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
AbbVie (ABBV)
4.9604 of 5 stars
$167.74+0.7%3.70%58.24Moderate Buy$203.37
Eli Lilly and Company (LLY)
4.9914 of 5 stars
$753.41+3.2%0.69%81.45Moderate Buy$1,007.94
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines